喹硫平合并丙戊酸镁缓释片治疗双相障碍躁狂发作的对照研究

目的：观察喹硫平和利培酮合并丙戊酸镁缓释片治疗双相躁狂发作的疗效及不良反应。方法：将78例双相躁狂发作患者随机分为喹硫平组（喹硫平合并丙戊酸镁缓释片）和利培酮组（利培酮合并丙戊酸镁缓释片），疗程6周，分别在治疗前及治疗后第1、2、4、6周未采用Beck—Rafaelsen躁狂量表（BRMS）、不良反应量表（TESS）评定疗效及药物不良反应。结果：治疗6周末，喹硫平组痊愈率76．92％（30／39），有效率94．87％（37／39）；利培酮组痊愈率71．79％（28／39），有效率92．31％（36／39）。两组疗效尢屁著性差异（P〉0．05）。两组均出现不良反应，喹硫平组不良反应发生率低，程度轻。结论：喹硫平和利培酮合并丙戊酸镁缓释片治疗双相躁狂发作的疗效相当，喹硫平合并丙戊酸镁缓释片起效快，安全性高，不良反应少，依从性好。

A control study on Quetiapine and Risperidon with Magnesium Valproate Sutaiued Release in treatment of mania of bipolar disorder

Objective：To observe the efficacy and safety of Quetiapine and Risperidon with Magnesium Valproate Sutaiued Release in the treatment of mania of bipolar disorder. Methods ：78 patients were randomly assignet to two groups. Quetiapin with Magnesium Valproate Sutaiued Release group and Risperidon with Magnesium Valproate Sutaiued Release group. For 6 week, Beck - Rafaelsen （BRMS） and Treatment Emergent Symptams Scale （ TESS ） were evaluate the clinical efficacy and safely, before treatment and after treatment thel ,2,4,6th week. Results ： At the ends of 6th week treatment, effectual and effective rat was 76.92% （ 30/39 ） and 94. 87 % （ 37/39 ）, in the Quetiapine group and 71.79 % （ 28/39 ） and 92.31% （ 36/39 ） in the Risperidon group. There were no significant in efficacy between two groups （ P 〉 0.05 ）. The adverse effects were less and milder in Quetiapin group. Conclusions ： Quetiapine and Risperidon with Magnesium Valproate Sutaiued Release have equivalent efficacy in the treatment of mania of bipolar disorder. Quetiapin group took effect more quickly, higher safety and better compliance.